English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 21 December 2020, 19:00 HKT/SGT
Share:
China Medical System (00867.HK) MSCI-ESG Rating Upgraded to AA, Reaching Global Level

HONG KONG, Dec 21, 2020 - (ACN Newswire) - Morgan Stanley Capital International (MSCI) issued a report on December 17 upgrading the ESG (Environmental, Social and Governance) Rating for China Medical System Holdings Limited ("China Medical System"), a well-established, innovation-driven specialty pharma with a focus on sales & marketing in China. China Medical System's ESG Rating has been upgraded from "BBB" to "AA", surpassing 88% of companies in the global pharmaceutical industry, symbolizing that the Company has attained a level among its global peers in ESG management.

MSCI recognized China Medical System's outstanding performance in Corporate Governance, Corporate Behavior, Product Safety and Quality, Human Capital Development, and Access to Health Care, noting that the Company "Leads peers in business ethics and talent management practices". MSCI also gave a positive assessment of the Company's Corporate Behavior, "China Medical System has evidence of detailed policies on business ethics and corruption".

There are seven levels of the MSCI-ESG Rating, from the highest to the lowest are AAA, AA, A, BBB, BB, B, and CCC. Among them, companies with AA or AAA ratings are considered to be industry leaders in managing the most significant ESG risks and opportunities. This year, China Medical System's MSCI-ESG Rating has been upgraded by three levels, from BB to AA.

According to the Company, "Receiving the AA ESG Rating from MSCI reflected China Medical System's long-term focus and resource investment on ESG management and information disclosure, and affirmed the Company's compliance focus and solid business practices. In recent years, with leadership from the Board of Directors, the Company's ESG-related policies have increasingly improved, ESG practices are more standardized, and ESG management is constantly refined.

"In the future, through self-challenge and transcendence, China Medical System will continuously pursue higher corporate governance goals. The Company will continuously regard innovation as its driving force, to fulfill the unmet medical needs, and contribute to the integrated development of society, the environment, and civilization."


Topic: Rating Report
Source:

Sectors: Daily Finance, Daily News, BioTech, Healthcare & Pharm
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2021 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Latest Press Releases
Anticancer Agent "Tazverik Tablets 200mg" (Tazemetostat Hydrobromide) Approved In Japan For EZH2 Gene Mutation-positive Follicular Lymphoma  
June 23, 2021 14:20 HKT/SGT
DENSO Invests in Seurat Technologies to Accelerate Development of Metal Additive Manufacturing  
June 23, 2021 13:54 HKT/SGT
Blockpass Accepted to FCA Regulatory Sandbox  
June 23, 2021 13:00 HKT/SGT
Woven Alpha Automated Mapping Platform and Mitsubishi Fuso Collaborate on Latest HD Mapping Technology for Advanced Driver Assistance Systems Functionality  
June 23, 2021 12:38 HKT/SGT
Watch Borneo Jazz Festival Free This 25-27 June  
June 23, 2021 10:00 HKT/SGT
ILgamos going ILGON. New project, same goal.  
June 23, 2021 10:00 HKT/SGT
Fujitsu Demonstrates High Performance Simulations for Industrial Use Cases with Commercial Applications on the World's Fastest Supercomputer, Fugaku  
June 23, 2021 09:41 HKT/SGT
Fujitsu, City of Kawasaki Strengthen Cooperation to Realize a Sustainable "Future City"  
June 23, 2021 09:25 HKT/SGT
HYPEBEAST LTD. (0150.HK) Sees Record Profitability Despite Covid-19 Challenges, Looks Ahead To Growth  
June 22, 2021 21:03 HKT/SGT
Wanchain Makes LTC Smart Contract Compatible, Adds Litecoin to Cross-Chain Blockchain Infrastructure  
June 22, 2021 21:00 HKT/SGT
More Press release >>
 Events:
More events >>
Copyright © 2021 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6653 1210 | Tokyo: +81 3 6859 8575